| P50 | author | Geke A P Hospers | Q100383982 |
| | Michel van Kruchten | Q130278944 |
| P2093 | author name string | Marianne G Rots | |
| | Nadine Martinet | |
| | Fahimeh Falahi | |
| P2860 | cites work | Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 |
| | Establishing, maintaining and modifying DNA methylation patterns in plants and animals | Q24630397 |
| | Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities | Q24644274 |
| | Optical control of mammalian endogenous transcription and epigenetic states | Q28505596 |
| | ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering | Q29615505 |
| | CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 |
| | Epigenetic modifications and human disease | Q29619753 |
| | Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types | Q30423124 |
| | Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells | Q31149698 |
| | A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer | Q33267359 |
| | Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272) | Q33372152 |
| | FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 |
| | Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer | Q33379343 |
| | Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers | Q33381378 |
| | Phase I study of 5-azacytidine (NSC-102816) . | Q33382259 |
| | CRISPRs and epigenome editing. | Q52422947 |
| | Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer | Q67537639 |
| | Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study | Q80358623 |
| | Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas | Q83324615 |
| | Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer | Q84784256 |
| | A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies | Q84912549 |
| | The heterochromatin protein 1 (HP1) family: put away a bias toward HP1. | Q37229600 |
| | Histone deacetylase inhibitor induced modulation of anti-estrogen therapy | Q37382851 |
| | Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. | Q37400592 |
| | Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. | Q37592077 |
| | Histone lysine methylation and demethylation pathways in cancer | Q37800638 |
| | The adjustable nucleosome: an epigenetic signaling module | Q38013367 |
| | Targeting epigenetic readers in cancer. | Q38034797 |
| | Epigenetic modifications in breast cancer and their role in personalized medicine | Q38125297 |
| | PET imaging of oestrogen receptors in patients with breast cancer | Q38147545 |
| | Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer | Q38150711 |
| | A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. | Q38395319 |
| | Towards sustained silencing of HER2/neu in cancer by epigenetic editing | Q39132647 |
| | Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells | Q39155908 |
| | Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity | Q39230783 |
| | Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes | Q39848851 |
| | Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. | Q40093675 |
| | Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. | Q40174195 |
| | Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. | Q40199783 |
| | Dynamics and memory of heterochromatin in living cells. | Q41940196 |
| | Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. | Q42452150 |
| | Specific transcriptional enhancement of inducible nitric oxide synthase by targeted promoter demethylation | Q42813999 |
| | Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma | Q42942114 |
| | A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. | Q43698918 |
| | Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. | Q44259975 |
| | HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. | Q45259942 |
| | Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. | Q45976113 |
| | Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. | Q45995871 |
| | Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors | Q46958949 |
| | Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 |
| | Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma | Q33394324 |
| | Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene | Q33698044 |
| | Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. | Q33738694 |
| | Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesis | Q33739319 |
| | Aberrant epigenetic landscape in cancer: how cellular identity goes awry | Q34149629 |
| | Development of programmable small DNA-binding molecules with epigenetic activity for induction of core pluripotency genes | Q34190537 |
| | Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells | Q34258435 |
| | Cancer genetics and epigenetics: two sides of the same coin? | Q34287662 |
| | Locus-specific editing of histone modifications at endogenous enhancers | Q34369340 |
| | Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins | Q34376497 |
| | Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter | Q34382768 |
| | Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? | Q34417159 |
| | Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group | Q34622291 |
| | Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer | Q34711457 |
| | Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. | Q34968336 |
| | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer | Q35034708 |
| | Epigenetic therapy for breast cancer | Q35162148 |
| | Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS. | Q35617265 |
| | Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. | Q35640316 |
| | Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines | Q35833879 |
| | Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells | Q35851931 |
| | Epigenetic reprogramming of cancer cells via targeted DNA methylation. | Q36012682 |
| | Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat | Q36245380 |
| | Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo | Q36363994 |
| | Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes | Q36435079 |
| | A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study | Q36528653 |
| | Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents | Q36645808 |
| | Epigenetic regulation of estrogen signaling in breast cancer | Q36891892 |
| | HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade | Q36912547 |
| | Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a | Q36938662 |
| | De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes | Q36968883 |
| | Epigenetic resensitization to platinum in ovarian cancer | Q36979382 |
| | Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer | Q37031561 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | epigenomics | Q3589153 |
| | breast neoplasm | Q23929670 |
| | genetic epigenesis | Q64443099 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 412 | |
| P577 | publication date | 2014-07-29 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer | |
| P478 | volume | 16 | |